venetoclax,bgb-11417,zanubrutinib
beigene,abbvie,roche
['toci', 'dlbcl', 'zanubrutinib', 'bgb-11417', 'lymsm', 'nhl', 'venetoclax', 'cll']
congress | #ash22 , presented data from the first in-human phase i trial of bgb-11417. bgb-11417 is more potent and selective than venetoclax. no pts discontinued due to aes. 33% cr rate in pts treated with bgb-11417 monotherapy.
#lymsm #medicalcongress 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm